Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Hironori Yamaguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8371-9410; OpenAlex author ID A5035941668, A5078389128. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 10

  1. Real-world oncological and pathological outcomes after neoadjuvant chemotherapy with gemcitabine plus S-1 for resectable pancreatic cancer: A propensity score-… Last author DOI 10.1016/j.suronc.2026.102386↗
  2. Diagnostic Biomarkers for Pancreatic Ductal Adenocarcinoma Using Non-Targeted Metabolomic Analysis. Co-author DOI 10.3390/cancers18040684↗
  3. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  4. Metformin reshapes the tumor microenvironment and enhances prognosis in invasive pancreatic ductal adenocarcinoma with diabetes mellitus. Co-author DOI 10.21037/jgo-2025-457↗
  5. Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy for Patients with Massive Malignant Ascites Secondary to Pancreatic Cancer: A Report of Two Patie… First author DOI 10.2169/internalmedicine.2191-23↗
  6. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  7. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  8. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  9. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Co-author DOI 10.1007/s10637-016-0369-0↗
  10. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naohiro Sata · 4 shared papers, 2024–2026 · strength 0.90
  2. Joji Kitayama · 5 shared papers, 2016–2026 · strength 0.84
  3. Masanobu Taguchi · 2 shared papers, 2025–2026 · strength 0.44
  4. Yoshiyuki Meguro · 2 shared papers, 2024–2026 · strength 0.42
  5. Kenichi Aizawa · 1 shared paper, 2026 · strength 0.28
  6. Hirofumi Sonoda · 1 shared paper, 2026 · strength 0.28
  7. Satoshi Kobayashi · 2 shared papers, 2022–2023 · strength 0.22
  8. Hiroshi Ishii · 2 shared papers, 2022–2023 · strength 0.22
  9. Naohiro Okano · 2 shared papers, 2022–2023 · strength 0.22
  10. Masato Ozaka · 2 shared papers, 2022–2023 · strength 0.22
  11. Akiko Todaka · 2 shared papers, 2022–2023 · strength 0.22
  12. Junji Furuse · 2 shared papers, 2022–2023 · strength 0.22
  13. Makoto Ueno · 2 shared papers, 2022–2023 · strength 0.22
  14. Rei Takahashi · 1 shared paper, 2025 · strength 0.20
  15. Naminatsu Takahara · 3 shared papers, 2014–2022 · strength 0.20
  16. Hiroyuki Isayama · 3 shared papers, 2014–2022 · strength 0.20
  17. Yousuke Nakai · 3 shared papers, 2014–2022 · strength 0.20
  18. Sohei Satoi · 2 shared papers, 2016–2022 · strength 0.17
  19. Kentaro Sudo · 1 shared paper, 2023 · strength 0.12
  20. Satoaki Nakamura · 1 shared paper, 2023 · strength 0.12
  21. Naoya Kato · 1 shared paper, 2023 · strength 0.12
  22. Toshio Nakagohri · 1 shared paper, 2023 · strength 0.12
  23. Nobumasa Mizuno · 1 shared paper, 2023 · strength 0.12
  24. Tatsuya Ioka · 1 shared paper, 2023 · strength 0.12
  25. Masafumi Ikeda · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.